Todd Kremin

From:

Matt Samuel [mcs@barronpartners.com]

Sent:

Monday, June 05, 2006 7:26 PM

To:

Henry Warner

Subject:

RE: Biosafe Medical Letter of Intent

Follow Up Flag: Follow up

Flag Status:

Red

Henry,

I talked to Andrew and he is very firm on the price, so let me know what your board's initial response is. I also talked to him about the Capex number, and he said something about upkeep needs for the facility including replacing your roof? Andrew was not certain, but does this sound framiliar? Get back to me when you get a chance.

Matthew C T Samuel Junior Analyst Barron Partners LP 730 Fifth Avenue, 25th Floor

New York, NY 10019 tel: 212-359-0205 fax: 646-607-2223 mcs@barronpartners.com www.barronpartners.com

From: Henry Warner [mailto:hwarner@ebiosafe.com]

Sent: Monday, June 05, 2006 10:52 AM

To: Matt Samuel

Cc: Robert Trumpy; Andrew B. Worden Subject: RE: Biosafe Medical Letter of Intent

Matt:

Thanks for the LOI. Before I forward this on to legal and accounting, let me ask 2 quick questions:

- 1. In talking to Andrew, I understood that Barron's valuation formula uses a 7 multiple applied to a corrected EBITDA. With a \$1.85M EBITDA less \$400,000 in new "public costs" and \$180,000 in recurring capital, I get a corrected EBITDA of \$1.27. This number times 7 gives a cap of approximately \$8.9M. Your proposal appears to be valued at approximately \$5M. Please explain what I have misunderstood.
- 2. In correcting EBITDA for the public entity, a credit of \$180,000 in "recurring capital expenditures" is listed. Did this come from our numbers? Please explain what this is.

Thanks.

Hank

Henry A. Warner Chief Executive Officer BIOSAFE Medical Technologies, inc. 847-234-8111

From: Matt Samuel [mailto:mcs@barronpartners.com]

Sent: Friday, June 02, 2006 1:08 PM

To: Henry Warner

Cc: Robert Trumpy; 'Andrew B. Worden'

Page 2 of 2 Page 2 of 2

Case 1:07-cv-11135-JSR

Document 14-16

Filed 04/30/2008

Subject: Biosafe Medical Letter of Intent

Mr. Warner,

I have attached the Barron Partners letter of Intent for Biosafe Medical Technologies. Please review the terms, and feel free to contact me with any questions. Thank you for your time and we look forward to becoming your financial partner.

Regards,

Matthew C T Samuel Junior Analyst Barron Partners LP 730 Fifth Avenue, 25th Floor New York, NY 10019 tel: 212-359-0205 fax: 646-607-2223 mcs@barronpartners.com www.barronpartners.com

The information contained in this communication may be confidential, is intended only for the use of the recipient named above, and may be legally privileged. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication, or any of its contents, is strictly prohibited. If you have received this communication in error, please re-send this communication to the sender and delete the original message and any copy of it from your computer system. Thank you.